Statistics for First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer
Total visits
| views | |
|---|---|
| First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer | 5 |
Total visits per month
| views | |
|---|---|
| January 2024 | 0 |
| February 2024 | 0 |
| March 2024 | 0 |
| April 2024 | 5 |
| May 2024 | 0 |
| June 2024 | 0 |
| July 2024 | 0 |
File Visits
| views | |
|---|---|
| Pegram2021FirstHuman-CCBYNCND.pdf | 28 |
Top country views
| views | |
|---|---|
| United States | 4 |
| South Korea | 1 |
Top city views
| views | |
|---|---|
| Bloomington | 3 |
| Gangnam-gu | 1 |
| Muncie | 1 |